After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Valued at a market cap of $10.8 billion, Viatris Inc. (VTRS) is a healthcare company headquartered in Canonsburg, ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the ...

Viatris said on Friday that its experimental eye ointment failed to clear buildup or debris in the eyes in a late-stage study in patients with an inflammatory eye condition.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Viatris (VTRS) stock dips after its experimental therapy for eyelid inflammation fails a Phase 3 trial. Read more here.

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

That's why it was notable when Viatris (VTRS-1.44%) announced a 9.1% increase in its quarterly dividend from $0.11 to $0.12 per share earlier this month. But can the stock afford the dividend hike?

Viatris said on Friday that its experimental ophthalmic ointment failed to meet the main goal of a late-stage study in patients with an eye condition that causes inflammation.